SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-051317
Filing Date
2020-11-05
Accepted
2020-11-05 16:13:01
Documents
16
Period of Report
2020-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K - Q3-20 EARNINGS ctmx-8k_20201105.htm   iXBRL 8-K 39167
2 EX-99.1 - Q3-20 EARNINGS RELEASE ctmx-ex991_71.htm EX-99.1 326183
3 GRAPHIC gltgb2s0bn4p000001.jpg GRAPHIC 9470
4 GRAPHIC gltgb2s0bn4p000005.jpg GRAPHIC 22322
5 GRAPHIC gltgb2s0bn4p000004.jpg GRAPHIC 33242
  Complete submission text file 0001564590-20-051317.txt   607781

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20201105.xsd EX-101.SCH 5752
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20201105_lab.xml EX-101.LAB 20232
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20201105_pre.xml EX-101.PRE 12069
9 EXTRACTED XBRL INSTANCE DOCUMENT ctmx-8k_20201105_htm.xml XML 3702
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 201290582
SIC: 2834 Pharmaceutical Preparations